1. MR staging karcinoma rektuma : kaj želi klinik izvedeti od radiologaAnja Meden Boltežar, Nina Boc, 2022, published scientific conference contribution Abstract: Pri bolnikih s karcinomom rektuma je v sklopu zamejitvenih preiskav glede na trenutne smernice potrebno opraviti MR preiskavo medenice. Pri tem je pomembna tako tehnična izvedba preiskave, kot tudi struktura samega izvida, ki ga pripravi radiolog. Ključni podatki, ki jih mora vsebovati izvid so: T in N status, oddaljenost od anokutane in anorektalne linije, podatek o infiltraciji analnega kompleksa, odnos tumorja glede na mezorektalno fascijo in podatek o ekstramuralni vaskularni invaziji. Za dobro izvedbo preiskave in pripravo izvida je ključna komunikacija med napotnim zdravnikom in radiologom. Podatki s katerimi želi radiolog razpolagati med pripravo izvida so: izvid digitorektalnega pregleda, izvid rektoskopije ali kolonoskopije z opisano globino na kateri leži tumorska formacija in patohistološki izvid tumorske formacije. Dobra komunikacija v smislu posredovanja izvidov vseh opravljenih preiskav in kliničnega statusa je še toliko bolj pomembna v sklopu sledenja po neoadjuvantnem zdravljenju, saj je le s slikovnimi preiskavami včasih težko ločiti med postterapevtskimi spremembami in ostankom tumorja.
Keywords: rak rektuma, sistemsko zdravljenje, rak prebavil
Published in DiRROS: 13.01.2023; Views: 84; Downloads: 18
 Full text (96,17 KB) |
2. Priporočila za obravnavo bolnikov s pljučnim rakomMartina Vrankar, Nina Boc, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But-Hadžić, Anton Crnjac, Eva Ćirić, Tanja Čufer, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik-Kramberger, Maja Ivanetič Pantar, Staša Jelerčič, Veronika Kloboves-Prevodnik, Mile Kovačević, Luka Ležaič, Mateja Marc-Malovrh, Katja Mohorčič, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačić, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar, 2022, not set Keywords: elektronske knjige
Published in DiRROS: 24.11.2022; Views: 158; Downloads: 34
Full text (3,01 MB)
This document has many files! More... |
3. |
4. |
5. Contrast-enhanced ultrasound for evaluation of tumor perfusion and outcome following treatment in a murine melanoma modelMaja Brložnik, Nina Boc, Maja Čemažar, Maša Bošnjak, Monika Savarin, Nataša Kejžar, Gregor Serša, Darja Pavlin, Simona Kranjc Brezar, 2021, original scientific article Published in DiRROS: 23.09.2022; Views: 149; Downloads: 84
Full text (1,07 MB)
This document has many files! More... |
6. BAP1-defficient breast cancer in a patient with BAP1 cancer syndromeAna Blatnik, Domen Ribnikar, Vita Šetrajčič Dragoš, Srdjan Novaković, Vida Stegel, Biljana Grčar-Kuzmanov, Nina Boc, Barbara Perić, Petra Škerl, Gašper Klančar, Mateja Krajc, 2022, original scientific article Abstract: BAP1 cancer syndrome is a rare and highly penetrant hereditary cancer predisposition. Uveal melanoma, mesothelioma, renal cell carcinoma (RCC) and cutaneous melanoma are considered BAP1 cancer syndrome core cancers, whereas association with breast cancer has previously been suggested but not confirmed so far. In view of BAP1 immunomodulatory functions, BAP1 alterations could prove useful as possible biomarkers of response to immunotherapy in patients with BAP1-associated cancers. We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry. She carried a germline BAP1 likely pathogenic variant (c.898_899delAG p.(Arg300Glyfs*6)). In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel. This case strengthens the evidence for including breast cancer in the BAP1 cancer syndrome tumor spectrum with implications for future cancer prevention programs. It also indicates immune checkpoint inhibitors might prove to be an effective treatment for BAP1-deficient breast cancer.
Keywords: BAP1, breast cancer, hereditary cancer syndromes, immunotherapy
Published in DiRROS: 19.09.2022; Views: 132; Downloads: 62
Full text (1,12 MB) |
7. |
8. |
9. |
10. |
